Palvella Therapeutics (NASDAQ: PVLA) okays equity plan share boost
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Palvella Therapeutics, Inc. stockholders approved an amendment to the company’s 2024 Equity Incentive Plan, increasing the authorized shares issuable under the plan by 750,000 shares. This amendment had been previously approved by the Board of Directors, subject to stockholder approval, and became effective immediately at the 2026 Annual Meeting.
As of April 13, 2026, there were 14,323,686 outstanding common shares entitled to vote. Stockholders elected three Class III directors—George M. Jenkins, Todd C. Davis and John Doux, M.D.—to serve until the 2029 Annual Meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the 2026 fiscal year.
Stockholders approved, on an advisory basis, 2025 compensation for named executive officers and chose to hold future advisory votes on executive compensation every year. They approved both the equity plan amendment and a potential adjournment proposal, although adjournment was ultimately unnecessary.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Equity plan share increase: 750,000 shares
Shares outstanding on record date: 14,323,686 shares
Auditor ratification votes for: 11,557,687 votes
+3 more
6 metrics
Equity plan share increase
750,000 shares
Additional authorized shares under 2024 Equity Incentive Plan
Shares outstanding on record date
14,323,686 shares
Common stock outstanding as of April 13, 2026
Auditor ratification votes for
11,557,687 votes
Ernst & Young LLP ratified for 2026 fiscal year
Say-on-pay advisory votes for
10,008,180 votes
2025 compensation of named executive officers
Equity amendment votes for
7,692,709 votes
Approval of Plan Amendment increasing issuable shares by 750,000
Frequency "every year" votes
9,183,170 votes
Preferred frequency of advisory say-on-pay votes
Key Terms
Equity Incentive Plan, broker non-votes, emerging growth company, independent registered public accounting firm, +2 more
6 terms
Equity Incentive Plan financial
"amendment to the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan to increase the authorized shares"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
broker non-votes financial
"Votes For ... Votes Withheld ... Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
independent registered public accounting firm financial
"Ernst &Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
advisory vote financial
"approved, on an advisory basis, the compensation of the Company’s named executive officers"
An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.
record date financial
"As of April 13, 2026, the record date for the Annual Meeting, there were 14,323,686 outstanding shares"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
FAQ
What equity plan change did Palvella Therapeutics (PVLA) stockholders approve?
Stockholders approved an amendment to the 2024 Equity Incentive Plan adding 750,000 additional shares authorized for issuance. The Board had previously approved this amendment subject to stockholder approval, and it became effective immediately at the 2026 Annual Meeting.
Which directors were elected at Palvella Therapeutics’ 2026 Annual Meeting?
Stockholders elected George M. Jenkins, Todd C. Davis and John Doux, M.D. as Class III directors. They will serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified or they otherwise cease serving.
Did Palvella (PVLA) stockholders ratify the company’s independent auditor for 2026?
Yes. Stockholders ratified the appointment of Ernst & Young LLP as Palvella’s independent registered public accounting firm for the 2026 fiscal year. The ratification vote received strong support, with the vast majority of votes cast in favor.
How often will Palvella Therapeutics hold advisory votes on executive compensation?
Stockholders indicated a preference to hold advisory votes on named executive officer compensation every year. In light of this result, the Board determined that Palvella will conduct an annual advisory vote on executive pay until the next required frequency vote.
Was the adjournment proposal at Palvella’s 2026 Annual Meeting used?
Stockholders approved a proposal allowing adjournment of the Annual Meeting if votes were insufficient to pass the equity plan amendment. Although this adjournment authority was approved, it was not needed because Proposal 5 received sufficient support at the meeting.